StageZero Life Sciences Ltd.
SZLSF
$0.0021
-$0.025-92.25%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | 51.42% | -61.77% | 78.68% | -1,722.39% | -1,722.39% |
| Total Depreciation and Amortization | -143.83% | -26.51% | -69.30% | -77.51% | -77.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -26.84% | -173.44% | -88.86% | 113.40% | 113.40% |
| Change in Net Operating Assets | -53.65% | 63.12% | -77.80% | -27.88% | -27.88% |
| Cash from Operations | -78.45% | -985.92% | 58.38% | 167.23% | 167.23% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -56.08% | -- | -- |
| Total Debt Repaid | 86.38% | 89.22% | 4.43% | -72.38% | -72.38% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 81.91% | 273.68% | -70.44% | -177.31% | -177.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 85.79% | -45.52% | -200.97% | -194.13% | -194.13% |
